Catalytic nucleic acids, ribozymes and deoxyribozymes can act as efficientribonucleases and degrade target RNA molecules by complementary Watson-Crick base pairing and catalytic cleavage of their phosphodiesterinternucleotide bonds. This ability makes ribozymes and deoxyribozymes potent molecular tools for therapeutic applications. Recent achievements inribozymes design and technology enable the preparation of ribozymes whichcan be efficiently expressed in cellular systems, co-localize with the targetmRNA and exhibit high intracellular activity. Several examples of preclinical andclinical trials of ribozymes directed toward viral genes (HBV, HCV, HIV-1) andoncogenes are discussed in this review.
Operational Program Digital Poland, 2014-2020, Measure 2.3: Digital accessibility and usefulness of public sector information; funds from the European Regional Development Fund and national co-financing from the state budget.
Sep 24, 2020
Aug 19, 2020
|Rybozymy w medycynie||Sep 24, 2020|
Ziółkowski, Piotr Babula- Skowrońska, Danuta Kaczmarek, Małgorzata Cieśla, Agata Sadowski, Jan
Sierant, Małgorzata Nawrot, Barbara
Nowak, Jacek K.